Our laboratory is involved in the research activities of the CarDia project (2022 – 2025; see below)
In particular, we focus on the following research areas:
- Synthesis and study of the effects of new hepatoselective analogues of human insulin for the potential treatment of type 1 and type 2 diabetes mellitus (M. Rossmeisl in collaboration with J. Jiracek at the Institute of Organic Chemistry and Biochemistry CAS).
- Testing NRF2 activators to improve adipose tissue function and their use in stimulating the synthesis and secretion of insulin-sensitizing lipokines in the context of exercise (M. Rossmeisl in collaboration with L. Rossmeislova at the 3rd Faculty of Medicine, Charles University).
- Use of novel synthetic analogues of natural neuropeptides as potential drugs against obesity and type 2 diabetes mellitus (J. Kopecky in collaboration with L. Maletinska at the Institute of Organic Chemistry and Biochemistry CAS).
- Role of adipose tissue metabolim in development of cardiac cachexia (J. Kopecky in collaboration with V. Melenovsky and M. Haluzik at the Institute of clinical and experimental medicine).
Related publication: Brezinova et al. 2020 BBA-Mol Cell Biol L; Janovska et al. 2020 J Cachexia, Sarcopenia Muscle
Project supported by National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) - Funded by the European Union – Next Generation EU.